Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Short Bowel Syndrome Market Size Changed, over the years?

The market size of short bowel syndrome has seen considerable growth in recent years. Predicted to escalate from $2.69 billion in 2024 to $3.09 billion in 2025, it is expected to have a compound annual growth rate (CAGR) of 14.9%. Factors contributing to the growth during the historic period include an increased prevalence of gastrointestinal disorders, a rise in healthcare spending and insurance coverage, enhancements in the post-operative treatment of SBS, a surge in the prevalence of Crohn’s disease and other GI disorders, and progress in parenteral nutrition formulations and delivery methods.

How Much Will the Short Bowel Syndrome Market Be Worth in 2029?

Over the coming years, the market size for short bowel syndrome is projected to experience swift expansion, increasing to $5.33 billion in 2029 with a compound annual growth rate (CAGR) of 14.6%. This market growth over the projected period can be traced back to a heightened incidence of short bowel syndrome (SBS), a trend towards parenteral and enteral nutrition therapy adoption, wider clinical research and drug development, a hike in healthcare spending, and an increase in awareness and early identification of SBS. The forecast period will likely see significant trends such as improvements in intestinal rehabilitation therapies, progression in small intestine transplantation techniques, the integration of telemedicine in SBS management, advanced technology in enteral feeding devices, and the use of artificial intelligence for SBS treatment planning.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

Which is the Largest Company in the Short Bowel Syndrome Market?

Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., Alnylam Pharmaceuticals, OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co. Ltd, Ardelyx Inc, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc., OxThera Inc. , Adocia SAS, EnteraBio Ltd, GLyPharma Therapeutic Inc.

What Are the Main Market Drivers in the Short Bowel Syndrome Industry?

As gastrointestinal diseases continue to become more common, the short bowel syndrome market is predicted to expand accordingly. Gastrointestinal diseases encompass a wide range of issues related to the digestive system, including conditions impacting the stomach, intestines, liver, pancreas, often leading to challenges in digestion and nutrient absorption. The rise of such diseases is majorly attributed to unhealthy eating practices that hamper gut health and stimulate inflammation. Gastrointestinal diseases can precipitate short bowel syndrome, as they might necessitate the surgical removal of damaged parts of the intestine, thereby diminishing its absorptive abilities. For example, the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canadian entity focused on bettering the lives of Crohn’s disease and ulcerative colitis patients, stated in September 2023 that with 825 prevalence per 100,000 in 2023, over 320,000 Canadians are living with IBD. As the anticipated yearly increase is 2.44%, it is estimated that by 2035, about 1.1% of the population, or around 470,000 Canadians will be living with IBD. Consequently, the escalating prevalence of gastrointestinal diseases is fueling the expansion of the short bowel syndrome market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

How Is the Short Bowel Syndrome Market Segments Structured?

The short bowel syndrome market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide (GLP-2), Growth Hormone, Glutamine

2) By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures, Other Diagnosis

3) By Treatment: Nutritional Therapy, Medications, Surgery, Transplant

4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucagon-Like Peptide (GLP-2): Teduglutide, Other GLP-2 Analogues

2) By Growth Hormone: Somatropin, Other Growth Hormone Therapies

3) By Glutamine: Oral Glutamine, Intravenous Glutamine

What Strategic Trends Are Transforming the Short Bowel Syndrome Market?

Key players in the short bowel syndrome sector are directing their strategic focus towards groundbreaking scientific advancements. These include interventions aimed at remedying intestinal failure, which could potentially revolutionize therapy options for patients suffering from gastrointestinal conditions. Intestinal failure is a severe health issue, characterized by the small intestine’s incapacity to absorb sufficient nutrients, fluids, or electrolytes for the body’s hydration and nutritional needs. In a related development, Ironwood Pharmaceuticals, Inc., a healthcare firm from the US, shared new study results in May 2024. The study involved the evaluation of apraglutide in adult patients diagnosed with short bowel syndrome and intestinal failure (SBS-IF). Apraglutide is a next-generation GLP-2 analog touted to potentially boost intestinal absorption and decrease dependency on parenteral support. These findings highlight the drug’s effectiveness, safety, and enduring advantages and reflect Ironwood’s dedication to crafting innovative treatments for gastrointestinal conditions.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

Which Global Regions Offer the Highest Growth in the Short Bowel Syndrome Market?

North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23515

This Report Delivers Insight On:

1. How big is the short bowel syndrome market, and how is it changing globally?

2. Who are the major companies in the short bowel syndrome market, and how are they performing?

3. What are the key opportunities and risks in the short bowel syndrome market right now?

4. Which products or customer segments are growing the most in the short bowel syndrome market?

5. What factors are helping or slowing down the growth of the short bowel syndrome market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model